CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed
Drug / intervention
Hepatitis B Vaccine (Recombinant) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00000745
NCT00000745Phase 1Completed
CompareCT.gov

A Phase I Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Aug 31, 2001·Updated Nov 4, 2021

In Brief

A Phase 1 clinical trial evaluating Hepatitis B Vaccine (Recombinant) and gp160 Vaccine (MicroGeneSys) for HIV Infections. Completed, across 2 sites.

Detailed Summary

To determine the reactivity and safety of HIV-1 recombinant envelope glycoprotein gp160. To determine the immunogenicity of gp160. Although recent advances have been made in antiviral therapy against AIDS, there is currently no cure. It is likely that ultimate control of the disease will depend on the development of safe and effective vaccines against HIV.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
CollaboratorsProtein Sciences Corporation

Timeline

Phase 1CompletedFinished
1991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 31, 2001
Study CompletionMay 1, 1991
TodayJul 2, 2026
Posted 24.8 years ago

Interventions

Hepatitis B Vaccine (Recombinant)biological

gp160 Vaccine (MicroGeneSys)biological